Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients aged 18-60~* Patients with a diagnosis of multiple sclerosis~Exclusion Criteria:~* Patients with a history or presence of chronic disease of the immune system other than MS~* Patients with a history or presence of malignancy, pulmonary or heart disease, etc.~* Pregnant or nursing (lactating) women~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- FTY720 0.5 mg (Type: EXPERIMENTAL): FTY720
- FTY720 1.25 mg (Type: EXPERIMENTAL): FTY720
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).